Care Pathway and Associated Costs of Patients Treated With CAR T-cells Based on SNDS Data

Novartis

Status: Completed

Conditions: Acute Lymphoblastic Leukemia (ALL); Diffuse Large B-cell Lymphoma

Study type: Observational

Funder types: Industry

Identifiers

NCT06392763

CCTL019A0FR03

Details and patient eligibility

About

This retrospective cohort study, based on the French medico-administrative database (SNDS), evaluated the care pathway, the effectiveness of management and the costs associated with patients treated with chimeric antigen receptor (CAR) T cells (CART-cells) (KYMRIAH or YESCARTA): paediatric and young adult patients (up to and including 25 years of age) with acute lymphoblastic leukaemia (ALL); and adult patients (18 years of age or older) with DLBCL.

Enrollment: 602 patients

Sex: All

Ages: 1+ year old

Volunteers: No Healthy Volunteers

Inclusion criteria

DLBCL population:

• Patients with hospitalisation for CAR T-cell administration from 2017 to 2020 AND
• Diagnosed with DLBCL (International Classification of Diseases [ICD-10 C833]) when receiving CAR-T AND
• Being 18 years of age or older.

ALL population:

• Patients with hospitalisation for CAR T-cell administration from 2017 to 2020 AND
• Diagnosed with ALL (ICD-10 C910) when receiving CAR-T AND
• Being 25 years of age or younger.

Exclusion criteria

DLBCL population:

• Patients hospitalised with a diagnosis other than DLBCL during the historical period or during the index stay.

ALL population:

• Patients hospitalised with a diagnosis other than ALL during the historical period or during the index stay.

Trial design

602 participants in 4 patient groups

KYMRIAH DLBCL

YESCARTA DLBCL

CAR-T DLBCL

KYMRIAH ALL